CHATHAM, NJ / ACCESS Newswire / March 31, 2025 /This post was written and published as a collaboration between the in-house ...

Tonix Pharmaceuticals (TNXP) announced the launch of TONIX ONE, a fully-integrated digital platform designed to help patients better understand ...

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) plummeted 19% lower on Wednesday noon after the company reported ...

Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 11.27%, which has investors questioning if this is right time to buy.

Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.

Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) plunged ~21% in the morning hours on Wednesday after the biotech fell short of ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would ...

Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, emphasized the company’s innovative efforts to improve patient access to necessary medications. He stated that TONIX ONE ...

CHATHAM, NEW JERSEY / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding ...